QuidelOrtho Corporation

Equities

QDEL

US2197981051

Market Closed - Nasdaq Other stock markets 21:00:00 16/01/2026 GMT			5-day change	1st Jan Change
33.20 ^USD	-6.16%		-1.32%	+16.25%

12-03	QuidelOrtho Corporation Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 01:00 PM
11-06	UBS Adjusts Price Target on QuidelOrtho to $31 From $26, Maintains Neutral Rating	MT

Transcript : QuidelOrtho Corporation, Q2 2025 Earnings Call, Aug 05, 2025

Published on 08/06/2025 at 02:23 am BST - Modified on 08/06/2025 at 06:21 am BST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Welcome to the QuidelOrtho Second Quarter 2025 Financial Results Conference Call and Webcast. [Operator Instructions] Please note, this conference

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about QuidelOrtho Corporation

12-03	QuidelOrtho Corporation Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 01:00 PM
11-06	UBS Adjusts Price Target on QuidelOrtho to $31 From $26, Maintains Neutral Rating	MT
11-06	QuidelOrtho Corporation, Q3 2025 Earnings Call, Nov 05, 2025
11-05	In vitro diagnostics firm QuidelOrtho beats Q3 revenue expectations	RE
11-05	Earnings Flash (QDEL) QuidelOrtho Corporation Reports Q3 Revenue $699.9M, vs. FactSet Est of $664.9M	MT
11-05	Earnings Flash (QDEL) QuidelOrtho Corporation Posts Q3 Adjusted EPS $0.80 per Share, vs. FactSet Est of $0.46	MT
11-05	QuidelOrtho Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 28, 2025	CI
11-05	Quidelortho Corporation Provides Earnings Guidance for Full Year 2025	CI
11-03	QuidelOrtho Receives FDA 510(k) Clearance for VITROS?? Immunodiagnostic Products hs Troponin I Assay	CI
11-03	QuidelOrtho Gets FDA Clearance for Cardiac Assay	MT
11-03	Quidelortho receives FDA 510(k) clearance for VITROS Immunodiagnostic Products hs Troponin I assay	RE
07/10/25	Citigroup Downgrades QuidelOrtho to Neutral From Buy, Adjusts Price Target to $33 From $40	MT
22/09/25	QuidelOrtho Corporation Announces Availability of QuICKVUE Influenza + SARS Test for Professional Use	CI
03/09/25	RBC Raises Price Target on QuidelOrtho to $62 From $60, Keeps Outperform Rating	MT
21/08/25	QuidelOrtho completes debt refinancing	RE
21/08/25	QuidelOrtho Completes $3.4 Billion in Debt Refinancing	MT
21/08/25	QuidelOrtho Corporation Enters into a Credit Agreement	CI
19/08/25	Quidelortho welcomes Erich Wolff as EVP, strategy & corporate development	RE
19/08/25	QuidelOrtho Corporation Appoints Erich Wolff as Executive Vice President, Strategy & Corporate Development	CI
13/08/25	QuidelOrtho Corporation Launches Certified Analyzer Program to Enhance Diagnostic Testing Access in Rural Hospitals	CI
07/08/25	UBS Cuts Price Target on QuidelOrtho to $26 From $29, Maintains Neutral Rating	MT
06/08/25	QuidelOrtho Fiscal Q2 Swings to Adjusted Earnings, Revenue Falls	MT
06/08/25	QuidelOrtho Corporation, Q2 2025 Earnings Call, Aug 05, 2025
05/08/25	QuidelOrtho Q2 revenue falls but beats expectations	RE
05/08/25	Earnings Flash (QDEL) QuidelOrtho Corporation Posts Q2 Adjusted EPS $0.12 per Share, vs. FactSet Est of $0.00	MT